Currently, several biomarkers—such as microsatellite instability-high (MSI-H), programmed death-ligand 1 (PD-L1), and tumor mutation burden (TMB)—are relatively well-established for predicting response to immunotherapy in GC (70, 71). This evidence concerns the gene CD274 and neoplasm.